BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

594131 patients between 2010-2015
(YEAR_OF_DIAGNOSIS>=2010 and YEAR_OF_DIAGNOSIS<=2015)

↓

58960 patients with pathologic confirmation
(BEHAVIOR=3 and DIAGNOSTIC_CONFIRMATION <= 4)

↓

52357 patients with histology codes for squamous, adenosquamous, adenocarcinoma*
squamous: 8070, 8071, 8072, 8073, 8074, 8075, 8076, 8078
adenosquamous: 8560, 8570; adenocarcinoma: 8140, 8144, 8255, 8384, 8480, 8481, 8482

↓

24668 patients who did not receive any surgery at the primary site
(RX_SUMM_SURG_PRIM_SITE=0)

↓

18369 patients with FIGO stage IB2-IVA disease
(data from CS_SITESPECIFIC_FACTOR_1 and if not available from TNM_CLIN_STAGE_GROUP)

↓

12772 patients who received EBRT
(RX_SUMM_RADIATION=1 or RX_SUMM_RADIATION=4)

↓

9724 patients who received 45-90 Gy
(RAD_REGIONAL_DOSE_CGY >= 4500 and RAD_REGIONAL_DOSE_CGY <= 9000)

↓

8825 patients who received radio-sensitizing chemotherapy
(RX_SUMM_CHEMO>=1 and RX_SUMM_CHEMO<=3)

↓

8823 patients with at least one month follow-up
(DX_LASTCONTACT_DEATH_MONTHS >= 1)

↓

3933 patients with data on mode of para-aortic lymph node evaluation
(CS_SITESPECIFIC_FACTOR_5=20 or CS_SITESPECIFIC_FACTOR_5=40)

↓

3796 patients after excluding misclassified cases based on pathology report
(data from variable REGIONAL_NODES_EXAMINED)

↓

3540 patients with data on the status of para-aortic lymph nodes (positive or negative)
(CS_SITESPECIFIC_FACTOR_4=0 or CS_SITESPECIFIC_FACTOR_4 = 10).